E.g., 10/18/2018
E.g., 10/18/2018

bioMérieux Unveils Full Microbiology Laboratory Automation Solutions

29 May, 2008

Automation Suite to be showcased at American Society for Microbiology (ASM) in Boston

bioMérieux and FIND to Collaborate on Infectious Disease Daignostics

15 May, 2008

bioMérieux, a leader in the field of in vitro diagnostics and FIND (the Foundation for Innovative New Diagnostics), a Swiss non-profit foundation, have signed a Memorandum of Understanding to jointly undertake development projects in the field of infectious disease diagnostics.

AOAC Approves bioMérieux VITEK® 2 Identification Cards for Biological Threat Organisms, E. coli O157, Listeria and Staph

07 May, 2008

Automated VITEK® 2 rapidly identifies foodborne organisms to ensure food quality and safety.

bioMérieux Receives the 2008 Diagnostic Marketing Association Creative Communications Award for Professional Relations

01 May, 2008

Award-winning WorkSafe initiative ensures blood culture safety as the first line of defense against Healthcare-Associated Infections

bioMérieux - First Quarter 2008 Business Review

29 April, 2008

Sales up 6.2% like-for-like.

bioMérieux Bestowed 2007 Frost & Sullivan European Healthcare-Associated Infection Control Technology Leadership Award

15 April, 2008

The 2007 European Healthcare-Associated Infection Control Technology Leadership Award is conferred upon bioMérieux in recognition of its unparalleled leadership and commitment toward healthcare-associated infection control and its pioneering and extensive work in this field.

University of Sunderland and bioMérieux Collaborate in New Research Significantly Improving the Identification of Pseudomonas Aeruginosa, a Major Cause of Death in Cystic Fibrosis Patients

03 April, 2008

A team of researchers from the University of Sunderland and bioMérieux, a leading company in the field of in vitro diagnostics, have achieved a new step in the fight against Pseudomonas aeruginosa, a bacterium responsible for deadly healthcare-associated infections, which kills tens of thousands of people throughout the world every year .1

2007 Financial Results

17 March, 2008

2007: Clear improvement in growth and in operating margin before non-recurring items

FDA Clears bioMérieux's VIDAS® NT-proBNP, a High Medical Value Test for Diagnosis of Heart Failure

13 March, 2008

bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration to market VIDAS® NT-proBNP, a test that helps the diagnosis of heart failure.

Pioneering Diagnostics